RU99105851A - COMPOSITIONS REPRESENTING THE MICROPARTICLES OF SUBSTANCES INSOLUBLE IN WATER AND METHOD FOR PRODUCING THEM - Google Patents

COMPOSITIONS REPRESENTING THE MICROPARTICLES OF SUBSTANCES INSOLUBLE IN WATER AND METHOD FOR PRODUCING THEM

Info

Publication number
RU99105851A
RU99105851A RU99105851/14A RU99105851A RU99105851A RU 99105851 A RU99105851 A RU 99105851A RU 99105851/14 A RU99105851/14 A RU 99105851/14A RU 99105851 A RU99105851 A RU 99105851A RU 99105851 A RU99105851 A RU 99105851A
Authority
RU
Russia
Prior art keywords
water
phospholipid
insoluble
compound
surfactant
Prior art date
Application number
RU99105851/14A
Other languages
Russian (ru)
Other versions
RU2186562C2 (en
Inventor
Инду ПЭРИК
Юлагарадж СЕЛВАРАДЖ
Original Assignee
Ресеч Трайангл Фармасьютикалс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ресеч Трайангл Фармасьютикалс Лтд. filed Critical Ресеч Трайангл Фармасьютикалс Лтд.
Publication of RU99105851A publication Critical patent/RU99105851A/en
Application granted granted Critical
Publication of RU2186562C2 publication Critical patent/RU2186562C2/en

Links

Claims (17)

1. Композиция из микрочастиц нерастворимого в воде вещества, содержащая частицы применяющегося в промышленности нерастворимого в воде вещества или плохо растворимого соединения, фосфолипид и по меньшей мере одно неионогенное, анионогенное или катионогенное поверхностно-активное вещество, в которой поверхностно-активное вещество или вещества приводят к тому, что значения средневзвешенных по объему размеров частиц нерастворимого в воде соединения не менее, чем на 50% меньше, чем у частиц, полученных при отсутствии поверхностно-активного вещества при такой же затрате энергии.1. A composition of microparticles of a water-insoluble substance containing particles of a commercially available water-insoluble substance or poorly soluble compound, a phospholipid and at least one nonionic, anionic or cationogenic surfactant in which the surfactant or substances leads to the fact that the values of the volume-weighted average particle sizes of a water-insoluble compound are not less than 50% less than those obtained in the absence of a surface-active substances with the same expenditure of energy. 2. Фармацевтическая композиция из микрочастиц нерастворимого в воде вещества, содержащая частицы применяющегося в промышленности нерастворимого в воде вещества или плохо растворимого соединения, фосфолипид и по меньшей мере одно неионогенное, анионогенное или катионогенное поверхностно-активное вещество, в которой поверхностно-активное вещество или вещества приводят к тому, что значения средневзвешенных по объему размеров частиц нерастворимого в воде соединения не менее, чем на 50% меньше, чем у частиц, полученных при отсутствии поверхностно-активного вещества при такой же затрате энергии. 2. A pharmaceutical composition of microparticles of a water-insoluble substance, containing particles of a industrially insoluble substance or a poorly soluble compound, a phospholipid and at least one nonionic, anionic or cationogenic surfactant in which the surfactant or substances moreover, the values of the volume-weighted average particle size of a water-insoluble compound are not less than 50% less than those obtained in the absence of nostno-active substance with the same energy expenditure. 3. Фармацевтическая композиция по п.2 для перорального приема, ингаляции, введения в глаза, в нос и для инъекций. 3. The pharmaceutical composition according to claim 2 for oral administration, inhalation, administration to the eyes, nose and injections. 4. Фармацевтическая композиция по п.3 в форме для инъекций, предназначенная для внутривенного, внутриартериального, внутримышечного, внутрикожного, подкожного, внутрисуставного, спинномозгового, эпидурального, внутрикостного, внутрибрюшного, внутриопухолевого введения, введения в мочевой пузырь, внутриочагового и субконьюктивального введения. 4. The pharmaceutical composition according to claim 3 in the form for injection, intended for intravenous, intraarterial, intramuscular, intracutaneous, subcutaneous, intraarticular, spinal, epidural, intraosseous, intraperitoneal, intratumoral administration, injection into the bladder, intrafocal and subconjunctival administration. 5. Высушенная суспензия состава по п.4, которую можно повторно суспендировать в водной или неводной среде. 5. The dried suspension of the composition according to claim 4, which can be re-suspended in an aqueous or non-aqueous medium. 6. Суспензия, полученный распылительной сушкой порошок, лиофилизированный порошок, гранулы или таблетки, состава по п.2. 6. The suspension obtained by spray drying the powder, lyophilized powder, granules or tablets, composition according to claim 2. 7. Композиция по п.1, в которой нерастворимое в воде соединение представляет собой соединение, используемое в биологии, или соединение, используемое в фотографии. 7. The composition according to claim 1, in which the water-insoluble compound is a compound used in biology, or a compound used in photography. 8. Композиция по п.1 или 2, отличающаяся тем, что поверхностно-активное вещество представляет собой сложный эфир полиоксиэтиленсорбита и жирной кислоты, блок-сополимер этиленоксида и пропиленоксида, тетрафункциональный блок-сополимер, полученный последовательным присоединением этиленоксида и пропиленоксида к этилендиамину, алкиларильный полиэфирсульфонат, полиэтиленгликоль, гидроксипропилметилцеллюлозу, додецилсульфат натрия, дезоксихолат натрия, цетилтриметиламмонийбромид или их комбинации. 8. The composition according to claim 1 or 2, characterized in that the surfactant is an ester of polyoxyethylene sorbitol and a fatty acid, a block copolymer of ethylene oxide and propylene oxide, a tetrafunctional block copolymer obtained by sequential addition of ethylene oxide and propylene oxide to ethylene diamine, an alkylaryl polyethersulfonate , polyethylene glycol, hydroxypropyl methylcellulose, sodium dodecyl sulfate, sodium deoxycholate, cetyltrimethylammonium bromide, or combinations thereof. 9. Композиция по п.1 или 2, отличающаяся тем, что фосфолипид представляет собой яичный фосфолипид, или фосфолипид растительного происхождения, или полусинтетический, или синтетический в частично или полностью гидрированной форме, или в виде соли, или свободного вещества, такой как фосфатидилхолин, Phospholipon 90H или натриевая соль димиристоилфосфатидилглицерина, фосфатидилэтаноламин, фосфатидилсерин, фосфатидная кислота, липофосфолипиды или их комбинации. 9. The composition according to claim 1 or 2, characterized in that the phospholipid is an egg phospholipid, or a phospholipid of plant origin, or semi-synthetic, or synthetic in partially or fully hydrogenated form, or in the form of a salt or free substance, such as phosphatidylcholine, Phospholipon 90H or sodium salt of dimyristoylphosphatidylglycerol, phosphatidylethanolamine, phosphatidylserine, phosphatidic acid, lipophospholipids, or combinations thereof. 10. Способ изготовления обладающих субмикрометровым и микрометровым размером стабильных частиц нерастворимого в воде или плохо растворимого в воде применяющегося в промышленности соединения с использованием природных или синтетических фосфолипидов, причем указанный процесс включает уменьшение размера частиц посредством ультразвуковой обработки, гомогенизации, размола, микропсевдоожижения и осаждения или перекристаллизации и осаждения этого соединения с использованием осаждения посредством агента, препятствующего растворению, или растворителя, включая осаждение из надкритической жидкости, в присутствии фосфолипида и по меньшей мере одного неионогенного, анионогенного или катионогенного поверхностно-активного вещества. 10. A method of manufacturing stable sub-micron and micro-sized particles of water-insoluble or poorly water-soluble compounds used in industry using natural or synthetic phospholipids, said process comprising particle size reduction by ultrasonic treatment, homogenization, milling, microfluidization and precipitation or recrystallization and precipitating this compound using precipitation by a dissolution inhibitor, and and solvent precipitation including from supercritical fluids in the presence of phospholipid and at least one nonionic, anionic or cationic surfactant. 11. Способ изготовления микрочастиц нерастворимого в воде или плохо растворимого в воде соединения, включающий стадии: (1) перемешивания частиц нерастворимого в воде или плохо растворимого в воде применяющегося в промышленности соединения с фосфолипидом и по меньшей мере одним неионогенным, анионогенным или катионогенным поверхностно-активным веществом с последующей (2) передачей этой смеси энергии, достаточной для образования частиц соединения, обладающих средневзвешенным по объему размером частиц не менее, чем на 50%, меньшим, чем у частиц, полученных в присутствии поверхностно-активного вещества при такой же затрате энергии. 11. A method of manufacturing microparticles of a water-insoluble or poorly water-soluble compound, comprising the steps of: (1) mixing particles of a water-insoluble or poorly water-soluble compound used in industry with a phospholipid and at least one nonionic, anionic or cationogenic surface-active substance with subsequent (2) transfer of this mixture of energy sufficient for the formation of particles of a compound having a particle-weighted average particle size of not less than 50% less than that of eggs obtained in the presence of a surfactant at the same energy expenditure. 12. Способ по п.10 или 11, отличающийся тем, что фосфолипид представляет собой яичный фосфолипид, или фосфолипид растительного происхождения, или полусинтетический, или синтетический в частично или полностью гидрированной форме, или в виде соли, или свободного вещества, такой как фосфатидилхолин, Phospholipon 90H или натриевая соль димиристоилфосфатидилглицерина, фосфатидилэтаноламин, фосфатидилсерин, фосфатидная кислота, липофосфолипиды или их комбинации. 12. The method according to claim 10 or 11, characterized in that the phospholipid is an egg phospholipid, or a plant-derived phospholipid, or semi-synthetic, or synthetic in partially or fully hydrogenated form, or in the form of a salt, or free substance, such as phosphatidylcholine, Phospholipon 90H or sodium salt of dimyristoylphosphatidylglycerol, phosphatidylethanolamine, phosphatidylserine, phosphatidic acid, lipophospholipids, or combinations thereof. 13. Способ по п.10 или 11, отличающийся тем, что поверхностно-активное вещество представляет собой сложный эфир полиоксиэтиленсорбита и жирной кислоты, блок-сополимер этиленоксида и пропиленоксида, тетрафункциональный блок-сополимер, полученный последовательным присоединением этиленоксида и пропиленоксида к этилендиамину, алкиларильный полиэфирсульфонат, полиэтиленгликоль, гидроксипропилметилцеллюлозу, додецилсульфат натрия, дезоксихолат натрия, цетилтриметиламмонийбромид или их комбинации. 13. The method according to claim 10 or 11, characterized in that the surfactant is an ester of polyoxyethylene sorbitol and a fatty acid, a block copolymer of ethylene oxide and propylene oxide, a tetrafunctional block copolymer obtained by sequential addition of ethylene oxide and propylene oxide to ethylene diamine, an alkylaryl polyethersulfonate , polyethylene glycol, hydroxypropyl methylcellulose, sodium dodecyl sulfate, sodium deoxycholate, cetyltrimethylammonium bromide, or combinations thereof. 14. Способ по п.10 или 11, отличающийся тем, что поверхностно-активное вещество присутствует в концентрации, превышающей критическую концентрацию мицеллообразования. 14. The method according to claim 10 or 11, characterized in that the surfactant is present in a concentration exceeding the critical micelle concentration. 15. Способ по п.10 или 11, отличающийся тем, что соединение представляет собой соединение, используемое в биологии, или соединение, используемое в фотографии. 15. The method according to claim 10 or 11, characterized in that the compound is a compound used in biology, or a compound used in photography. 16. Композиция, представляющая собой микрочастицы, приготовленные с помощью способа по п.10. 16. A composition comprising microparticles prepared using the method of claim 10. 17. Композиция, представляющая собой микрочастицы, приготовленные с помощью способа по п.11. 17. A composition comprising microparticles prepared using the method according to claim 11.
RU99105851/14A 1996-08-22 1997-03-28 Composites presenting water-insoluble substance microparticles and method of their producing RU2186562C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70148396A 1996-08-22 1996-08-22
US08/701,483 1996-08-22

Publications (2)

Publication Number Publication Date
RU99105851A true RU99105851A (en) 2001-02-20
RU2186562C2 RU2186562C2 (en) 2002-08-10

Family

ID=24817566

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99105851/14A RU2186562C2 (en) 1996-08-22 1997-03-28 Composites presenting water-insoluble substance microparticles and method of their producing

Country Status (20)

Country Link
US (2) US5922355A (en)
EP (1) EP0925061B1 (en)
JP (1) JP2000516244A (en)
KR (1) KR100542816B1 (en)
CN (1) CN1303985C (en)
AT (1) ATE314055T1 (en)
AU (1) AU719085B2 (en)
CA (1) CA2263102C (en)
CZ (1) CZ299790B6 (en)
DE (1) DE69734988T2 (en)
ES (1) ES2252780T3 (en)
HK (1) HK1021140A1 (en)
HU (1) HU226608B1 (en)
IL (1) IL128632A (en)
NO (1) NO325197B1 (en)
NZ (1) NZ333844A (en)
PL (1) PL192560B1 (en)
RO (1) RO120603B1 (en)
RU (1) RU2186562C2 (en)
WO (1) WO1998007414A1 (en)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
DE69637441T2 (en) * 1995-10-17 2009-03-05 Jagotec Ag ADMINISTRATION OF UNSUCCESSFUL MEDICINAL PRODUCTS
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) * 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
WO1999049846A2 (en) 1998-03-30 1999-10-07 Rtp Pharma Inc. Compositions containing microparticles of water-insoluble substances and method for their preparation
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
ATE259220T1 (en) * 1998-05-29 2004-02-15 Skyepharma Canada Inc MICROPARTICLES PROTECTED AGAINST HEAT AND METHOD FOR THE TERMINAL STEAM STERILIZATION OF SAME
JP4693238B2 (en) 1998-06-19 2011-06-01 オバン・エナジー・リミテッド Method for producing submicron particles of water insoluble compounds
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
EP2266542A3 (en) * 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6969529B2 (en) 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
AU767737B2 (en) * 1998-11-20 2003-11-20 Skyepharma Canada Inc. Method of preparing stable suspensions of insoluble microparticles
SK288117B6 (en) * 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
TR200101790T2 (en) 1998-12-23 2001-10-22 Idea Ag. Formula developed for uncommon in vivo topical applications
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
DE19932157A1 (en) * 1999-07-13 2001-01-18 Pharmasol Gmbh Process for the gentle production of ultra-fine microparticles and nanoparticles
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
WO2001021154A2 (en) * 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
JP5102423B2 (en) 2000-04-20 2012-12-19 オバン・エナジー・リミテッド Improved treatment of water-insoluble drug particles
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
JP4763957B2 (en) 2000-05-10 2011-08-31 オバン・エナジー・リミテッド Media milling
ATE424811T1 (en) 2000-08-31 2009-03-15 Jagotec Ag GROUND PARTICLES
AU6294501A (en) * 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20020058065A1 (en) * 2000-09-20 2002-05-16 Pol-Henri Guivarc'h Insoluble drug particle compositions with improved fasted-fed effects
US7998507B2 (en) 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
CA2428785C (en) * 2000-11-20 2011-04-26 Henry William Bosch Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6534088B2 (en) * 2001-02-22 2003-03-18 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
CN1522140A (en) * 2001-05-18 2004-08-18 兰贝克赛实验室有限公司 Oxcarbazepine dosage forms
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
JP2004537401A (en) * 2001-08-08 2004-12-16 ブラウン ユニバーシティ リサーチ ファウンデーション Fine grinding method of hydrophobic drug
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
AU2002337692B2 (en) 2001-09-26 2007-09-13 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US8663687B2 (en) * 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
PT1441737E (en) 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
ES2306785T3 (en) * 2001-11-02 2008-11-16 The Governors Of The University Of Alberta COMPOSITIONS OF MICELAS CONTAINING PEGILATED PHOSPHOLIPIDS AND A PHOTOSENSITIZER.
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
GB0127832D0 (en) * 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
ATE508735T1 (en) 2001-12-19 2011-05-15 Novartis Ag PULMONARY ADMINISTRATION OF AMINOGLYCOSIDES
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
AU2003210517A1 (en) 2002-02-04 2003-09-02 Elan Pharma International, Ltd. Drug nanoparticles with lysozyme surface stabiliser
US6861066B2 (en) * 2002-03-11 2005-03-01 Health Plus International Inc. Method for the delivery of a biologically active agent
US20060280761A1 (en) * 2002-03-11 2006-12-14 Health Plus International, Inc. Nanofluidized B-12 composition and process for treating pernicious anemia
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
EP1490030B2 (en) * 2002-03-20 2010-07-14 Elan Pharma International Limited Nanoparticulate compositions of angiogenesis inhibitors
US7862751B2 (en) * 2002-04-15 2011-01-04 Map Pharmaceuticals, Inc. Formulation of fine particles using liquefield or dense gases
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US7763278B2 (en) 2002-06-10 2010-07-27 Elan Pharma International Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
US6998051B2 (en) * 2002-07-03 2006-02-14 Ferro Corporation Particles from supercritical fluid extraction of emulsion
EP1551457A1 (en) * 2002-07-16 2005-07-13 Elan Pharma International Limited Liquid dosage compositions of stable nanoparticulate active agents
EP1549293A1 (en) * 2002-09-16 2005-07-06 Vasogen Ireland Limited Accelerating recovery from trauma
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
CN1243538C (en) * 2002-11-21 2006-03-01 武汉利元亨药物技术有限公司 Ursolic acid bean phospholipid nano particle freeze drying powder for ampoule agent and its preparation method
EP2557785A1 (en) * 2002-11-29 2013-02-13 Sony Corporation Delay controlled decoding method and apparatus
US20060134145A1 (en) * 2002-12-06 2006-06-22 Otsuka Pharmaceutical Factory, Inc. Propofol-containing fat emulsions
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
JP2004323444A (en) * 2003-04-25 2004-11-18 Hamamatsu Kagaku Gijutsu Kenkyu Shinkokai Freeze-dried microparticle preparation and method for producing the same
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
JP2007501683A (en) * 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド Sterilization of nanoparticle active substance dispersions by gamma irradiation
GB0319797D0 (en) * 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
KR20060130162A (en) * 2004-01-08 2006-12-18 와이어쓰 Directly compressible pharmaceutical composition for the oral admimistration of cci-779
NZ548195A (en) * 2004-01-14 2011-01-28 Gilead Sciences Inc Lipid-based dispersions useful for drug delivery
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
JP2007520555A (en) * 2004-02-05 2007-07-26 バクスター・インターナショナル・インコーポレイテッド Dispersants prepared by use of self-stabilizing agents
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP1750677B1 (en) * 2004-05-28 2017-02-01 Imaginot Pty Ltd. Oral therapeutic compound delivery system
WO2006026592A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Oral administration of poorly absorbed drugs, methods and compositions related thereto
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
US20080171687A1 (en) * 2004-09-16 2008-07-17 Abraxis Bioscience, Inc. Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
JP2008530145A (en) * 2005-02-15 2008-08-07 ワイス CCI-779 formulation that can be administered orally
JP5080445B2 (en) * 2005-04-13 2012-11-21 アボット ゲーエムベーハー ウント コー. カーゲー Ultrafine particle suspension, method for gently producing ultrafine particles and use thereof
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
CA2608930A1 (en) * 2005-06-14 2006-12-28 Baxter International Inc. Pharmaceutical formulations for minimizing drug-drug interactions
CA2628630A1 (en) * 2005-11-15 2007-05-24 Baxter International Inc. Compositions of lipoxygenase inhibitors
CA2629904C (en) 2005-11-28 2018-07-10 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US7703698B2 (en) * 2006-09-08 2010-04-27 Kimberly-Clark Worldwide, Inc. Ultrasonic liquid treatment chamber and continuous flow mixing system
US7810743B2 (en) 2006-01-23 2010-10-12 Kimberly-Clark Worldwide, Inc. Ultrasonic liquid delivery device
KR100919731B1 (en) * 2006-05-11 2009-09-29 재단법인서울대학교산학협력재단 Chitosan microsheres for vaccine delivery containing polyether as stabilizer
US8034286B2 (en) * 2006-09-08 2011-10-11 Kimberly-Clark Worldwide, Inc. Ultrasonic treatment system for separating compounds from aqueous effluent
US9283188B2 (en) * 2006-09-08 2016-03-15 Kimberly-Clark Worldwide, Inc. Delivery systems for delivering functional compounds to substrates and processes of using the same
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
US20090152176A1 (en) * 2006-12-23 2009-06-18 Baxter International Inc. Magnetic separation of fine particles from compositions
US7673516B2 (en) * 2006-12-28 2010-03-09 Kimberly-Clark Worldwide, Inc. Ultrasonic liquid treatment system
US7712353B2 (en) 2006-12-28 2010-05-11 Kimberly-Clark Worldwide, Inc. Ultrasonic liquid treatment system
MX2009008582A (en) 2007-02-11 2009-10-30 Map Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile.
ES2423929T3 (en) 2007-02-16 2013-09-25 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition containing fine particle oil based suspension
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US7998322B2 (en) * 2007-07-12 2011-08-16 Kimberly-Clark Worldwide, Inc. Ultrasonic treatment chamber having electrode properties
US7785674B2 (en) * 2007-07-12 2010-08-31 Kimberly-Clark Worldwide, Inc. Delivery systems for delivering functional compounds to substrates and processes of using the same
US7947184B2 (en) * 2007-07-12 2011-05-24 Kimberly-Clark Worldwide, Inc. Treatment chamber for separating compounds from aqueous effluent
US8858892B2 (en) 2007-12-21 2014-10-14 Kimberly-Clark Worldwide, Inc. Liquid treatment system
US8454889B2 (en) 2007-12-21 2013-06-04 Kimberly-Clark Worldwide, Inc. Gas treatment system
US8632613B2 (en) 2007-12-27 2014-01-21 Kimberly-Clark Worldwide, Inc. Process for applying one or more treatment agents to a textile web
US8215822B2 (en) * 2007-12-28 2012-07-10 Kimberly-Clark Worldwide, Inc. Ultrasonic treatment chamber for preparing antimicrobial formulations
US8057573B2 (en) 2007-12-28 2011-11-15 Kimberly-Clark Worldwide, Inc. Ultrasonic treatment chamber for increasing the shelf life of formulations
US9421504B2 (en) 2007-12-28 2016-08-23 Kimberly-Clark Worldwide, Inc. Ultrasonic treatment chamber for preparing emulsions
US20090166177A1 (en) 2007-12-28 2009-07-02 Kimberly-Clark Worldwide, Inc. Ultrasonic treatment chamber for preparing emulsions
US8206024B2 (en) 2007-12-28 2012-06-26 Kimberly-Clark Worldwide, Inc. Ultrasonic treatment chamber for particle dispersion into formulations
GB0803969D0 (en) * 2008-03-04 2008-04-09 Britannia Pharmaceuticals Ltd Improved phospholipid and method for its production
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
GB0818403D0 (en) * 2008-10-08 2008-11-12 Univ Leuven Kath Aqueous electrophoretic deposition
WO2010040648A2 (en) * 2008-10-06 2010-04-15 Katholieke Universiteit Leuven, K.U.Leuven R&D Functional layers of biomolecules and living cells, and a novel system to produce such
US8163388B2 (en) 2008-12-15 2012-04-24 Kimberly-Clark Worldwide, Inc. Compositions comprising metal-modified silica nanoparticles
US8685178B2 (en) 2008-12-15 2014-04-01 Kimberly-Clark Worldwide, Inc. Methods of preparing metal-modified silica nanoparticles
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2266546A1 (en) 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
IT1398857B1 (en) 2009-06-10 2013-03-21 Univ Padova FOSPHOLIPID POLYMERIC CONJUGATES
FR2949063B1 (en) * 2009-08-11 2011-09-30 Pf Medicament PHARMACEUTICAL COMPOSITION COMPRISING A DHA ESTER FOR PARENTERAL ADMINISTRATION
US9023886B2 (en) * 2009-11-10 2015-05-05 Celgene Corporation Nanosuspension of a poorly soluble drug via microfluidization process
PE20121359A1 (en) * 2009-12-10 2012-10-15 Merck Patent Gmbh PHARMACEUTICAL COMPOSITION INCLUDING OLIGOPEPTIDES
EP2559347B1 (en) * 2010-04-16 2014-11-12 San-Ei Gen F.F.I., INC. Method for masking flavor of curcumin
JP2013540827A (en) 2010-10-29 2013-11-07 ウエスタン ユニバーシティ オブ ヘルス サイエンシズ Three-mixed preparation
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CA2830511C (en) 2011-03-18 2021-09-14 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising aripiprazole lauroxil and sorbitan laurate
JP2014532655A (en) * 2011-10-31 2014-12-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Nano suspension process
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
US9993556B2 (en) 2012-03-19 2018-06-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty glycerol esters
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
EP3718536A1 (en) 2012-09-19 2020-10-07 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN105612284B (en) * 2013-11-07 2018-01-23 尤妮佳股份有限公司 Absorbent commodity Composite material and its manufacture method
MA39495A (en) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Ltd ARIIPIPRAZOLE FORMULATIONS WITH HIGHER INJECTION RATES
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
RU2737893C2 (en) * 2015-08-11 2020-12-04 Айсью Медсинз Б.В. Pegylated lipid nanoparticle with a bioactive lipophilic compound
US20170320862A1 (en) 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
CN107875436B (en) * 2017-11-10 2020-02-18 杭州华微医疗科技有限公司 Sodium bicarbonate powder-loaded liquid embolic agent composition and application thereof
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN109091451B (en) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 Oil phase liquid crystal gel precursor preparation of hydrophilic medicine and preparation method thereof
EP4056038A1 (en) * 2021-03-10 2022-09-14 Basf Se Microparticles containing active substances

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56152739A (en) * 1980-04-25 1981-11-26 Tanabe Seiyaku Co Ltd Production of microcapsule
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
DE3421468A1 (en) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim LIPID NANOPELLETS AS A CARRIER SYSTEM FOR MEDICINAL PRODUCTS FOR PERORAL USE
FR2617047B1 (en) 1987-06-23 1991-05-10 Sanofi Sa TANNING RESISTANT GELATIN COMPOSITION, CAPSULES BASED ON THIS COMPOSITION AND THEIR PHARMACEUTICAL APPLICATION, IN PARTICULAR TO FENOFIBRATE
AU609242B2 (en) 1988-01-29 1991-04-26 Novartis Ag Cyclosporin compositions
FR2627696B1 (en) 1988-02-26 1991-09-13 Fournier Innovation Synergie NEW GALENIC FORM OF FENOFIBRATE
CA2013755C (en) * 1989-04-05 1993-11-30 Simon Benita Medicinal emulsions
US5389377A (en) * 1989-12-22 1995-02-14 Molecular Bioquest, Inc. Solid care therapeutic compositions and methods for making same
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
EP0570829B1 (en) 1992-05-18 2001-04-25 CicloMulsion AG Pharmaceutical composition for intravenous administration containing cyclosporin and method for its preparation
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
CA2091152C (en) * 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5639474A (en) 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
US5364633A (en) * 1994-03-14 1994-11-15 Dow Corning Corporation Silicone vesicles and entrapment
US5603951A (en) 1994-11-09 1997-02-18 Hanmi Pharm. Ind. Co., Ltd. Cyclosporin-containing soft capsule compositions
KR0167613B1 (en) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 Cyclosporin-containing soft capsule compositions
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
FR2730231B1 (en) 1995-02-02 1997-04-04 Fournier Sca Lab COMBINATION OF FENOFIBRATE AND VITAMIN E, USE IN THERAPEUTICS
FR2737121B1 (en) 1995-07-27 1997-10-03 Cl Pharma NEW GALENIC FORMULATIONS OF FENOFIBRATE AND THEIR APPLICATIONS
DE69637441T2 (en) * 1995-10-17 2009-03-05 Jagotec Ag ADMINISTRATION OF UNSUCCESSFUL MEDICINAL PRODUCTS

Similar Documents

Publication Publication Date Title
RU99105851A (en) COMPOSITIONS REPRESENTING THE MICROPARTICLES OF SUBSTANCES INSOLUBLE IN WATER AND METHOD FOR PRODUCING THEM
RU2186562C2 (en) Composites presenting water-insoluble substance microparticles and method of their producing
CN100346775C (en) Nanoparticulate core-shell systems and use thereof in pharmaceutical and cosmetic preparations
ZA200104069B (en) Dispersible phospholipid stabilized microparticles.
EP1079808B1 (en) Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
CA2556514C (en) Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same
US20130045275A1 (en) Sustained-release chitosan capsules comprising chitosan and phytic acid
JP2003521508A (en) Liposome
LT3201B (en) Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof
MXPA03002544A (en) Improved paclitaxel-based antitumor formulation.
WO1999049846A2 (en) Compositions containing microparticles of water-insoluble substances and method for their preparation
JP2007530683A (en) Enteric coating on an orally ingestible substrate
JP2004529966A (en) Oxcarbazepine preparation
US5556637A (en) Water containing liposome system
CA2660647C (en) A suspension comprising benzimidazole carbamate and a polysorbate
JP5494054B2 (en) Method for producing liposomes by two-stage emulsification
KR20090014205A (en) Hydrogel suspension and manufacturing process thereof
CN100350911C (en) Pharmaceutical compsn. comprising poorly water-soluble active ingredient, surfactant and water-soluble polymer
BG108458A (en) Pharmaceutical formulation having a masked taste and method for the production thereof
JP2758297B2 (en) Liposome preparation
JP4676763B2 (en) Compounds for oral preparation of active substances in need of taste masking
JP3103513B2 (en) Shark cartilage oral ingestion preparation
JPH06321772A (en) Water ribosome system and preparation of said ribosome system
JP2009505976A5 (en)
CA2412575C (en) Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone